Aspirin resistance: Effect of clinical, biochemical and genetic factors

被引:93
作者
FitzGerald, Richard [1 ]
Pirmohamed, Munir [1 ]
机构
[1] Univ Liverpool, Wolfson Ctr Personalised Med, Dept Pharmacol, Liverpool L69 3GL, Merseyside, England
基金
英国惠康基金;
关键词
Aspirin resistance; Aspirin; Cardiovascular disease; Anti-platelets; Platelet function testing; Pharmacogenetics; SOLUBLE CD40 LIGAND; LOW-DOSE ASPIRIN; PLATELET-FUNCTION TESTS; VON-WILLEBRAND-FACTOR; ACUTE CORONARY SYNDROME; INSENSITIVE EICOSANOID BIOSYNTHESIS; RECURRENT CARDIOVASCULAR EVENTS; ATHEROSCLEROSIS RISK-FACTORS; TRANSIENT ISCHEMIC ATTACK; C-REACTIVE PROTEIN;
D O I
10.1016/j.pharmthera.2011.01.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aspirin is one of the cornerstones of treatment for cardiovascular disease. However, some patients may be 'resistant' to its effect: this is associated with adverse cardiovascular outcomes and increased mortality. Measuring response to aspirin is often difficult and there is no accepted definition of aspirin resistance. Many assays are available to test aspirin sensitivity but most are not specific to aspirin and the degree of agreement between different assays is poor. Each assay has its own advantages and disadvantages, and there is currently no one assay that can be recommended for routine clinical practise. There are also many potential modifiers of aspirin response including aspirin dose, non-compliance, disease severity, genetic factors, inflammation, diabetes mellitus, hyperlipidaemia, smoking and interacting drugs. Treating the underlying cause may improve aspirin sensitivity but current data are contradictory with no large clinical trials that have addressed this. Further work is required in this area to determine whether and how aspirin resistance is important clinically, what the best measurement is phenotypically and how this should be used in clinical practise, and whether there are any genetic predisposing factors. This will require well designed prospective studies which take into account the numerous confounding factors that can modify aspirin resistance. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:213 / 225
页数:13
相关论文
共 153 条
[31]   Lack of aspirin effect: Aspirin resistance or resistance to taking aspirin? [J].
Cotter, G ;
Shemesh, E ;
Zehavi, M ;
Dinur, I ;
Rudnick, A ;
Milo, O ;
Vered, Z ;
Krakover, R ;
Kaluski, E ;
Kornberg, A .
AMERICAN HEART JOURNAL, 2004, 147 (02) :293-300
[32]   Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers [J].
Cox, Dermot ;
Maree, Andrew O. ;
Dooley, Michelle ;
Conroy, Ronan ;
Byrne, Michael F. ;
Fitzgerald, Desmond J. .
STROKE, 2006, 37 (08) :2153-2158
[33]   Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100 - A systematic review [J].
Crescente, Marilena ;
Di Castelnuovo, Augusto ;
Lacoviello, Licia ;
Vermylen, Jos ;
Cerletti, Chiara ;
de Gaetano, Giovanni .
THROMBOSIS AND HAEMOSTASIS, 2008, 99 (01) :14-26
[34]   Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis -: Results from the Dallas Heart Study [J].
de Lemos, JA ;
Zirlik, A ;
Schönbeck, U ;
Varo, N ;
Murphy, SA ;
Khera, A ;
McGuire, DK ;
Stanek, G ;
Lo, HS ;
Nuzzo, R ;
Morrow, DA ;
Peshock, R ;
Libby, P .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (10) :2192-2196
[35]   The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients - An analysis from the aspirin-induced platelet effect (ASPECT) study [J].
DiChiara, Joseph ;
Bliden, Kevin P. ;
Tantry, Udaya S. ;
Hamed, Miruais S. ;
Antonino, Mark J. ;
Suarez, Thomas A. ;
Bailon, Oscar ;
Singla, Anand ;
Gurbel, Paul A. .
DIABETES, 2007, 56 (12) :3014-3019
[36]   Platelet function measured by VerifyNow™ identifies generalized high platelet reactivity in aspirin treated patients [J].
Dichiara, Joseph ;
Bliden, Kevin P. ;
Tantry, Udaya S. ;
Chaganti, Srivasavi K. ;
Kreutz, Rolf P. ;
Gesheff, Tania B. ;
Kreutz, Yvonne ;
Gurbel, Paul A. .
PLATELETS, 2007, 18 (06) :414-423
[37]   What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? [J].
Dippel, DWJ ;
van Kooten, F ;
Leebeek, FWG ;
van Vliet, HHDM ;
Mehicevic, A ;
Li, SSC ;
Koudstaal, PJ .
CEREBROVASCULAR DISEASES, 2004, 17 (04) :296-302
[38]   Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid Determinants and Effect on Cardiovascular Risk [J].
Eikelboom, John W. ;
Hankey, Graeme J. ;
Thom, Jim ;
Bhatt, Deepak L. ;
Steg, P. Gabriel ;
Montalescot, Gilles ;
Johnston, S. Claiborne ;
Steinhubl, Steven R. ;
Mak, Koon-Hou ;
Easton, J. Donald ;
Hamm, Christian ;
Hu, Tingfei ;
Fox, Keith A. A. ;
Topol, Eric J. .
CIRCULATION, 2008, 118 (17) :1705-1712
[39]   Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial [J].
Eikelboom, JW ;
Hankey, GJ ;
Thom, J ;
Claxton, A ;
Yi, Q ;
Gilmore, G ;
Staton, J ;
Barden, A ;
Norman, PE .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (12) :2649-2655
[40]   Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events [J].
Eikelboom, JW ;
Hirsh, J ;
Weitz, JI ;
Johnston, M ;
Yi, Q ;
Yusuf, S .
CIRCULATION, 2002, 105 (14) :1650-1655